Alida Biosciences
Alida Biosciences (AlidaBio) is a San Diego-based biotech that sells the EpiPlex Platform, an NGS-based kit, software, and service offering for simultaneously detecting m6A, inosine, and pseudouridine RNA modifications alongside gene expression, serving academic, core-facility, biopharma, and diagnostics researchers.
- Company typePrivate
- Founded2020
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alida Biosciences does
Alida Biosciences, Inc. (commercial brand: AlidaBio) is a San Diego-based, Delaware-incorporated biotechnology company founded in 2020-2021 that develops the EpiPlex Platform, an end-to-end epitranscriptomics workflow for simultaneously detecting and quantifying RNA modifications (m6A, inosine, and pseudouridine) alongside gene expression from a single sequencing library. The core technology combines engineered non-antibody protein binders, proprietary RNA-modifying enzymes, and proximity barcoding chemistry to translate RNA modifications into NGS-readable barcodes, with a 7-hour total workflow (~3 hours hands-on) that accepts as little as 20 ng mRNA or 250 ng total RNA and is compatible with Illumina, Element Aviti, and Complete Genomics short-read sequencers. Downstream analysis is performed by EpiScout, a cloud (DNAnexus) and Docker-deliverable software package that uses a Hidden Markov Model plus random forest peak caller with spike-in normalization and an AlidaDiff differential analysis module.
The company serves academic and translational researchers, academic core facilities, and biopharma/diagnostics customers developing RNA-modification-targeted therapeutics and biomarkers. It generates revenue through four streams: one-time sales of EpiPlex kits (RNA Mod Encoding Kit, UDI Primer Kit) via direct e-commerce, recurring per-sample service revenue from Uni-Mod, Duo-Mod, and Tri-Mod send-sample profiling tiers, usage-based EpiScout Compute Tokens, and strategic biopharma collaboration programs (e.g., STORM Therapeutics for m6A biomarker discovery in METTL3 inhibitor trials). Distribution combines a WooCommerce/Stripe storefront, quote-based inside sales, a Certified Service Provider network anchored by Baylor College of Medicine's GARP Core, and direct enterprise sales for biopharma and clinical partnerships. The platform is protected by five US patents plus granted patents in Australia, China, and Japan (the latter licensed from Oxford University Innovation), and EpiPlex and EpiScout are registered US trademarks.
Alida Biosciences firmographics
Firmographics- Name
- Alida Biosciences
- Legal name
- Alida Biosciences, Inc.
- Website
- https://alidabio.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alida Biosciences (AlidaBio) is a San Diego-based biotech that sells the EpiPlex Platform, an NGS-based kit, software, and service offering for simultaneously detecting m6A, inosine, and pseudouridine RNA modifications alongside gene expression, serving academic, core-facility, biopharma, and diagnostics researchers.
- Ownership category
- akta.pro rank
Alida Biosciences industry classification
Industry- Product category
- Epitranscriptomics Research Tools
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industries
- Epigenomics & Chromatin Profiling Services (HLAGANAF), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Alida Biosciences is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Alida Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- EpiPlex Kits and Reagent Sales: One-time hardware sales of the EpiPlex RNA Mod Encoding Kit (8- and 24-sample kits, catalog 100108/100124), EpiPlex UDI Primer Kit (24/96 UDIs, catalog 224001/296001), and Starter Bundles via the alidabio.com storefront.
- EpiPlex Profiling Services (Uni-Mod / Duo-Mod / Tri-Mod): Recurring, per-sample service revenue for send-in RNA modification profiling (1-47, 48+, 72+, 96+ sample tiers) with EpiScout results delivered; turnkey alternative to running kits in-lab.
- EpiScout Compute Tokens: Usage-based / unit-priced access to EpiScout analysis pipeline on DNAnexus (1-sample/2-libraries, 8-sample/16-library, 24-sample/48-library tokens); required to run service or kit data through the cloud pipeline.
- Biopharma / Strategic Collaboration Programs: Strategic collaboration revenue from biopharma partners (e.g., STORM Therapeutics) using EpiPlex and EpiScout for clinical biomarker and translational research applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | One time/ perpetual license | EpiPlex RNA Mod Encoding Kit — 8 samples (16 libraries) or 24 samples (48 libraries), catalog 100108 / 100124 |
| Unit Pricing | One time/ perpetual license | EpiPlex UDI Primer Kit — 24 UDIs (up to 12 samples) or 96 UDIs (up to 48 samples), catalog 224001 / 296001 |
| Usage-based | Pay-as-you-go | EpiScout Compute Token — 1 sample (2 libraries), 8 samples (16 libraries), or 24 samples (48 libraries) |
| Subscription | Other | EpiPlex Services — Uni-Mod, Duo-Mod, Tri-Mod at 1-47, 48+, 72+, 96+ sample tiers |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels8 records
Alida Biosciences product offering
Product offeringCore offering
Alida Biosciences develops and commercializes the EpiPlex Platform, an end-to-end epitranscriptomics solution that detects and quantifies RNA modifications (m6A, inosine, and pseudouridine) alongside gene expression using proximity barcoding with engineered non-antibody protein binders and proprietary RNA-modifying enzymes. The company sells library preparation kits (EpiPlex RNA Mod Encoding Kit, UDI Primer Kit), the EpiScout cloud/Docker analysis software, and turnkey send-sample profiling services (Uni-Mod, Duo-Mod, Tri-Mod) to academic, biopharma, and diagnostics researchers.
Product overview
Alida Biosciences sells a single epitranscriptomics platform, the EpiPlex Platform, together with modular kits, software, and turnkey services that work interchangeably. The in-lab product line consists of the EpiPlex RNA Mod Encoding Kit (the core library prep chemistry for m6A and inosine with gene expression) and the add-on EpiPlex Unique Dual Index (UDI) Primer Kit for multiplexing, both analyzed by EpiScout Analysis Software (delivered as a DNAnexus cloud app or Docker image). Researchers who prefer not to run the assay themselves can purchase EpiPlex Services in three tiers — Uni-Mod (one modification), Duo-Mod (m6A + inosine), and Tri-Mod (m6A + inosine + pseudouridine) — which use the same chemistry, binders, and EpiScout pipeline. The same platform is also offered externally through AlidaBio Certified Service Providers such as Baylor College of Medicine's GARP Core.
Differentiator
Problem solved
Functional benefit
Brands
- EpiPlex: A platform of products and services for multi-target detection and quantification of RNA modifications (m6A, inosine, and pseudouridine) alongside gene expression, including EpiPlex RNA Mod Encoding Kit, EpiPlex UDI Primer Kit, and EpiPlex Services (Uni-Mod, Duo-Mod, Tri-Mod).
- EpiScout
Products and services
- EpiPlex RNA Mod Encoding Kit Library preparation kit (catalog # 100108 for 8 samples / 16 libraries, # 100124 for 24 samples / 48 libraries) enabling detection and relative quantification of m6A and inosine together with RNA expression in a single ~7-hour workflow with ~3 hours hands-on time, requiring as little as 20 ng mRNA or 250 ng total RNA. For academic, translational, clinical, and biopharma researchers.
- EpiPlex Unique Dual Index (UDI) Primer Kit Unique dual index primer kit (catalog # 224001 with 24 UDIs for up to 12 samples; # 296001 with 96 UDIs for up to 48 samples) that enables multiplexing and clear library identification on Illumina short-read sequencers, with kits combinable for up to 120 libraries (60 samples) per lane. For EpiPlex kit users running multiplexed sequencing.
- EpiScout Analysis Software End-to-end analysis software that turns EpiPlex sequencing data into RNA modification maps and RNA expression insights using ML peak calling (HMM + random forest ensemble), spike-in normalized quantification (Lambda Model System), and AlidaDiff differential analysis; delivers genome-browser-ready outputs (BAM, BED, bigWig) and count tables. Available on DNAnexus via EpiScout Compute Token or as a Docker image.
- EpiPlex Uni-Mod Service Turnkey send-sample profiling service for one of three RNA modifications (m6A, inosine, or pseudouridine) alongside gene expression, with EpiScout results delivered end-to-end. A 1-47 / 48+ / 72+ / 96+ sample tiered, quote-priced service for researchers who prefer not to run the assay in-lab.
- EpiPlex Duo-Mod Service Send-sample profiling service that simultaneously maps and quantifies m6A and inosine RNA modifications together with integrated RNA expression profiling for correlative insights from limited clinical samples. Quote-priced per sample tier.
- EpiPlex Tri-Mod Service First commercial NGS send-sample service enabling simultaneous detection and quantification of all three abundant RNA modifications (m6A, inosine, and pseudouridine) alongside RNA expression in a single workflow with single-base resolution via proprietary enzyme-driven chemistry. Targets academic and biopharma researchers, including clinical biomarker and translational studies.
Quantifiable outcome
- Detects m6A, inosine, and pseudouridine alongside gene expression in a single workflow (Tri-Mod)
- +4 more outcomes
Companies that use Alida Biosciences
Customer profileNamed customers9 records
Segments5 records
Ideal customer profiles3 records
Alida Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability5 records
Feature6 records
Alida Biosciences partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- STORM TherapeuticsflagshipStrategic collaboration announced January 8, 2026 under which STORM will use AlidaBio's EpiPlex and EpiScout NGS platforms to analyze m6A RNA modifications in clinical samples from cancer patients treated with STC-15 (first-in-class METTL3 inhibitor in Phase 1/2). Collaboration aims to correlate m6A changes with clinical response and identify biomarkers to guide patient selection for future trials.
- DNAnexuscoreCollaboration announced March 2025 to enhance RNA modification and expression analysis. EpiScout analysis software is distributed as a cloud app on the DNAnexus platform, with AlidaBio's Compute Tokens providing sample-level access to the pipeline; DNAnexus provides cloud compute infrastructure for EpiScout analysis.
- Baylor College of Medicine — Genomic and RNA Profiling (GARP) CoreflagshipFirst Certified Service Provider partner, announced June 9, 2025. GARP Core provides multiplexed RNA modification sequencing (m6A and inosine) as a paid service to investigators using the EpiPlex Assay after completing AlidaBio's training and validation program.
- Oxford University Innovation LimitedcoreLicensor of patents and patent applications (US 12,466,861; AU2020234063B2; CN113767111 B; JP 7707070 B2; and related filings) that cover AlidaBio's EpiPlex RNA Mod Encoding Kit.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Alida Biosciences competitors and assessment
Company assessmentBroad incumbents
- QIAGEN: QIAGEN is a broad sample-prep and molecular diagnostics incumbent offering RNA extraction, NGS library prep, and bioinformatics (QIAGEN Digital Insights) targeting the same translational and clinical research workflows as EpiPlex.
- Bio-Techne: Bio-Techne (R&D Systems, Tocris, ProteinSimple, ExoDx) is a broad life sciences research tools incumbent with antibodies, ELISAs, and analytic instruments covering RNA modification research through its R&D Systems antibody portfolio.
- Thermo Fisher Scientific: Thermo Fisher Scientific is the dominant life sciences tools incumbent spanning reagents, NGS library prep (Ion Torrent), and bioinformatics (Ion Reporter), addressing the same epitranscriptomics customers as part of a much broader portfolio.
- New England Biolabs: NEB is a broad incumbent in molecular biology enzymes and reagents with a large RNA biology catalog (NEBNext library prep kits), serving the same academic and translational research customers with overlapping NGS workflow tools.
Direct peers
- Abcam: Abcam is the dominant supplier of m6A and other RNA-modification antibodies used in MeRIP-seq, the antibody-based method that EpiPlex explicitly displaces. Both companies sell research tools for profiling RNA modifications to overlapping academic and translational customers.
- Lexogen: Lexogen sells RNA sequencing library prep kits and related services (QuantSeq, CORALL) targeting similar RNA biology and translational research customers as EpiPlex, with overlapping workflows in low-input and expression profiling.
- EpiCypher: EpiCypher develops chromatin and epigenetic research tools including nucleosome standards and emerging RNA modification assays, making it a comparable niche player in the epitranscriptomics and chromatin research tools space.
- Synaptic Systems: Synaptic Systems is a specialized antibody supplier offering high-quality m6A and other RNA-modification antibodies used in MeRIP-seq workflows, positioning it as a direct technology competitor to EpiPlex's non-antibody enrichment approach.
- Active Motif: Active Motif sells antibody-based m6A and other epitranscriptomic enrichment kits and chromatin/epigenetic research tools directly competing with EpiPlex in the RNA modification profiling workflow. They target the same academic and translational research market.
- Diagenode: Diagenode offers m6A and other RNA-modification IP-grade antibodies and kits plus epigenetics services, directly competing with EpiPlex's antibody-free proximity barcoding approach in the academic and translational research segment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Alida Biosciences social profiles
Digital presenceAlida Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alida Biosciences leadership team
Management profileNumber of profiles
Profiles7 records
Alida Biosciences funding detail
Funding detailFunding overview
Funding rounds6 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alida Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alida Biosciences
What does Alida Biosciences do?
Alida Biosciences develops and commercializes the EpiPlex Platform, an end-to-end epitranscriptomics solution that detects and quantifies RNA modifications (m6A, inosine, and pseudouridine) alongside gene expression using proximity barcoding with engineered non-antibody protein binders and proprietary RNA-modifying enzymes. The company sells library preparation kits (EpiPlex RNA Mod Encoding Kit, UDI Primer Kit), the EpiScout cloud/Docker analysis software, and turnkey send-sample profiling services (Uni-Mod, Duo-Mod, Tri-Mod) to academic, biopharma, and diagnostics researchers.
Is Alida Biosciences a public or private company?
Alida Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alida Biosciences founded?
Alida Biosciences was founded in 2020. It employs 11 to 50 people.
Where is Alida Biosciences based?
Alida Biosciences is headquartered in San Diego, United States, in the North America region.
How does Alida Biosciences make money?
Four revenue lines are on record. EpiPlex Kits and Reagent Sales are the primary driver. The others are epiPlex Profiling Services (Uni-Mod / Duo-Mod / Tri-Mod), epiScout Compute Tokens and biopharma / Strategic Collaboration Programs.
Who are Alida Biosciences's main competitors?
Broad incumbents on record are QIAGEN, Bio-Techne, Thermo Fisher Scientific and New England Biolabs. Direct peers are Abcam, Lexogen, EpiCypher, Synaptic Systems, Active Motif and Diagenode.
Does Alida Biosciences have an API?
No public API is recorded for Alida Biosciences.
What industry is Alida Biosciences in?
Alida Biosciences's product category is Epitranscriptomics Research Tools. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGANAF, Epigenomics & Chromatin Profiling Services. Its NAICS code is 541714.